BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.

Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.

Lundbeck has secured fast track designation from the US FDA for its investigational treatment, Lu AH69593, to treat narcolepsy.

GSK's newly approved ROS1-positive NSCLC drug, Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.

BMS enhances its AI computing power with NVIDIA's DGX SuperPOD as big pharma race to stay competitive within the shifting global landscape.

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

UK biotech financing recovery was present in the private markets in Q2 2026 as the sector contends with a tough global funding landscape.

Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugma ...

Evogene and ELEO have entered into a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the PCSK9 pathway for hyperlipidemia and cardiovascular ...

Japan is becoming a regenerative medicine hub, with ageing patients, clear regulations, universal insurance data, and globally aligned trial reforms.

Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989 in patients with mutCALR-expressing MPNs.

The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for its gout drug, dotinurad.